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Abstract
There is increasing evidence suggesting that short telomeres and subsequent genomic instability contribute to malignant
transformation. Telomere shortening has been described as a mechanism to explain genetic anticipation in dyskeratosis
congenita and Li-Fraumeni syndrome. Since genetic anticipation has been observed in familial breast cancer, we aimed to
study telomere length in familial breast cancer patients and hypothesized that genetic defects causing this disease would
affect telomere maintenance resulting in shortened telomeres. Here, we first investigated age anticipation in mother-
daughter pairs with breast cancer in 623 breast cancer families, classified as BRCA1, BRCA2, and BRCAX. Moreover, we
analyzed telomere length in DNA from peripheral blood leukocytes by quantitative PCR in a set of 198 hereditary breast
cancer patients, and compared them with 267 control samples and 71 sporadic breast cancer patients. Changes in telomere
length in mother-daughter pairs from breast cancer families and controls were also evaluated to address differences
through generations. We demonstrated that short telomeres characterize hereditary but not sporadic breast cancer. We
have defined a group of BRCAX families with short telomeres, suggesting that telomere maintenance genes might be
susceptibility genes for breast cancer. Significantly, we described that progressive telomere shortening is associated with
earlier onset of breast cancer in successive generations of affected families. Our results provide evidence that telomere
shortening is associated with earlier age of cancer onset in successive generations, suggesting that it might be a mechanism
of genetic anticipation in hereditary breast cancer.
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Introduction
Genetic anticipation is the observation of progressively earlier
age of onset or an increase of severity of clinical features of a
genetic disorder as it is passed on to the next generation. The
molecular mechanisms underlying anticipation are largely un-
known, but it has been typically associated to trinucleotide repeat
expansions in several genetic diseases [1,2]. In cancer, genetic
anticipation has previously been described in several hereditary
cancer syndromes, such as hereditary non-polyposis colorectal
cancer (HNPCC) [3,4], familial leukemia [5], Li-Fraumeni
Syndrome[6–8] and also in familial breast and ovarian cancer
[9–11].
Telomere shortening has been more recently described as
another mechanism of anticipation, being associated with early
onset and severity of disease in genetic disorders, such as dy-
skeratosis congenita [12,13], a disease characterized by cutaneous
abnormalities, bone marrow failure and an increased predisposi-
tion to cancer, and in the Li-Fraumeni Syndrome [7,8]. Families
with dyskeratosis congenita have mutations in genes in the telo-
merase or shelterin complex, causing reduced telomerase activity.
Telomeres are nucleoprotein structures that protect the end of
chromosomes. Telomeres shorten with each cell cycle and there is
increasing evidence suggesting that short telomeres and subse-
quent genomic instability contribute to malignant transformation.
In this way, data from several case-control studies have indi-
cated that individuals with relatively short mean telomere lengths
might have an increased risk for developing cancer [14,15]. In
particular, telomere length and risk of breast cancer have been
evaluated in different studies, although disparities among the
results did not allow final conclusions [16–19].
Inherited predisposition to breast cancer accounts for approx-
imately 5% of all cases and is characterized by an autosomal
dominant pattern of inheritance, young age of onset and bilateral
breast cancer. Familial breast and ovarian cancer (FBOC) is
associated with inherited mutations mainly in two genes, BRCA1
and BRCA2. Women who have inherited mutations in either one
of these genes have a high risk of developing breast cancer, ovarian
cancer, and several other types of cancer during their lifetimes.
However, a large proportion of familial breast cancer is not caused
by mutations in BRCA1 or BRCA2. These non-BRCA1/2 breast
cancer families (referred to as BRCAX families) comprise a
histopathologically heterogeneous group, further supporting their
origin being from other genetic events [20].
PLoS Genetics | www.plosgenetics.org 1 July 2011 | Volume 7 | Issue 7 | e1002182Telomere length maintenance is a complex process controlled
by a large number of different proteins, and in addition to telo-
mere binding proteins, many other proteins commonly involved in
DNA repair are also found at telomeric ends [21]. BRCA1 and
BRCA2 genes are involved in repair of DNA double strand breaks.
Inherited defects in these genes lead to chromosomal instability
contributing to malignant cell transformation. Importantly, there
is evidence that BRCA1 localized at telomeres and may regulate
telomere length and stability [22–24]. In addition BRCA2 has
been very recently described to be implicated in telomere
replication [25].
Based on all these data we hypothesized that telomere shor-
tening may be associated to age anticipation in hereditary breast
cancer. In this study, we analyzed telomere length in DNA from
peripheral blood leukocytes in familial breast cancer cases and
evaluated generational changes in telomere length in mother-
daughter pairs with the aim to investigate the role of telomere
shortening and its potential implication as a mechanism of age
anticipation in familial breast cancer.
Results
Anticipation in the age of breast cancer onset in familial
breast cancer
The occurrence of age anticipation in mother-daughter pairs
with breast cancer was analyzed in 623 FBOC families, classified
as BRCA1 (40 families), BRCA2 (52 families), and BRCAX (531
families). The distributions of age at diagnosis for mother and
daughters showed a consistent shift to earlier ages in daughters
(Figure 1). Evidence for anticipation comparing the age of breast
cancer diagnosis in daughters and respective mothers from these
families was found after t-test in the three genetic groups. Breast
cancer was diagnosed at an average of 6.8 years earlier in
daughters in the BRCA1 families (p=0.002) (Table 1). In the
BRCA2 and BRCAX groups, a more significant earlier age of
diagnosis in daughters was found, being 12.1 years in the BRCA2
(p=2.9610
27) and 12.3 years in the BRCAX families (p=
1.5610
255). Therefore, significant differences were found in the
age of onset between mothers and daughters in the three groups,
showing the BRCA2 and BRCAX groups stronger apparent
anticipation effect than BRCA1 group.
Telomere length of hereditary and sporadic breast cancer
cases
In order to evaluate the hypothesis that telomere shortening
may be associated with the earlier onset of the disease, we
investigated the mean relative telomere length of blood leukocytes
in index cases from FBOC families, either BRCA1 (48 cases),
BRCA2 (45 cases), or BRCAX (105 cases), and compared with the
relative telomere length of a normal population of healthy women
covering an age range between 23 and 70 years (267 samples)
(Figure 2). Interestingly, telomere lengths in affected individuals
from BRCA1 and BRCA2 families were significantly shorter than
those in the control population after adjustment for age using the
line of best fit from controls (p,0.0001) (Figure 3). High risk
BRCAX families showed a more heterogeneous distribution of
telomere length, with cases of both short and long telomeres.
Adjusting for age, this group also demonstrated significant
differences to the controls (p=0.031) (Figure 3). We also compared
the mean telomere length in blood leukocytes from a group of 71
sporadic breast cancer patients. Importantly, age-adjusted telo-
mere length distribution in these cases did not differ from controls
(p=0.133) (Figure 2 and Figure 3). Therefore, hereditary but not
sporadic breast cancer seems to be characterized by short
telomeres, primarily in BRCA1 and BRCA2 mutation carriers,
but also in a subgroup of BRCAX.
Telomere length in mutation carriers and non-carriers
from BRCA1/2 families
Since BRCA1 or BRCA2 mutations were found associated with
short telomeres, we further explored whether the altered function
of these genes would be causing a reduction in telomere length or
Author Summary
The fact that accelerated telomere shortening accompa-
nies different premature aging syndromes and seems to
be associated with increased risk of cancer development
prompted us to analyze the role of telomere length in
hereditary breast cancer. In this study we found that
telomeres of peripheral blood cells from familial breast
cancer patients were significantly shorter than those from
the control population. Women carrying a mutation in
BRCA1 or BRCA2 genes, and a subset of BRCAX families,
were characterized by short telomeres. We also demon-
strated that genetic anticipation, the successive earlier age
of onset of cancer, in these families was associated with a
decrease of the telomere length in affected daughters
compared to their mothers. This is the first study
suggesting that telomere shortening may contribute to
anticipation in breast cancer families and that analysis of
telomere length in hereditary breast cancer may affect the
design of surveillance programs for affected families.
Figure 1. Anticipation effect in the age of breast cancer onset in the familial breast cancer genetic subgroups. Kaplan–Meier curves
showing the differences in age of onset of familial breast cancer in mothers and daughters in BRCA1 (left panel), BRCA2 (middle panel), and BRCAX
(right panel) families. Log-rank test p-values are represented for each group.
doi:10.1371/journal.pgen.1002182.g001
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environmental factors present in these families. We analyzed
telomere length of 19 affected women carrying BRCA1/2
mutations (8 BRCA1 and 11 BRCA2) and 22 sisters from the
same families (8 BRCA1 and 14 BRCA2) who did not inherit the
mutations (Figure 4). Affected BRCA1/2 mutation carriers
showed not only significantly shorter telomeres than the un-
related normal controls (p,0.0001) but also versus the healthy
sisters not carrying the mutation (p=0.034). Telomeres of these
healthy sisters do not significantly differ from the normal control
population (p=0.177) suggesting that short telomeres are not
likely the result of a predisposing genetic background or environ-
Table 1. Difference in the age of onset of breast cancer between mothers and daughters in hereditary breast cancer.
Mothers Daughters
n Mean age (years) ±s.d. n Mean age (years) ±s.d. Mean age difference ±s.d t-statistic t-test p value
BRCA1 40 47.6 611.8 49 40.2 610.2 6.8 616.2 3.165 0.002
BRCA2 52 55.6 612.7 66 44.1 610.2 12.1 614.0 5.196 2.9610
27
BRCAX 531 58.4 613.9 643 46.4 611.1 12.3 616.7 16.369 1.5610
255
Mean age of cancer development in mothers and daughters in the three groups, BRCA1, BRCA2 and BRCAX, of hereditary breast cancer. Statistical significance of the
difference between mothers and daughters was estimated by t-tests.
s.d. Standard deviation. Bilateral t-test was performed to assess the significance of the differences between mothers and daughters. Values for the t-statistic and the p-
value for the t-test are indicated.
doi:10.1371/journal.pgen.1002182.t001
Figure 2. Telomere length distribution in control, familial breast cancer, and sporadic breast cancer cases. Telomere length distribution
in peripheral blood leukocytes as a function of age for the control women population (n=267, grey circles) and for breast cancer cases (black circles).
Controls show the expected telomere length erosion with increasing age. Regression line for controls is drawn (y=20.0146x+1.585, R
2=0.144).
Comparison between control telomere length distribution and telomeres from 48 BRCA1 (A), 44 BRCA2 (B), 105 BRCAX (C), and 71 sporadic breast
cancer cases (D) is represented.
doi:10.1371/journal.pgen.1002182.g002
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sisters, but would rather be a consequence of the mutation in the
BRCA1/2 genes. So, it seems that haploinsufficiency for BRCA1
or BRCA2 in heterozygous women contributes to progressive
telomere shortening at a somatic and germline level, affecting the
age of cancer onset in successive generations. Because in the
BRCAX group the causing mutations are unknown, a similar
study cannot be performed, but it is possible that at least a
subgroup of BRCAX families characterized by shorter telomeres
were associated to mutations in other genes with a role in
telomere maintenance.
Stratification of BRCAX families by telomere length
To better characterize the subgroup of BRCAX families with
short telomeres, we divided breast cancer cases into quartiles of
telomere length, according to the telomere length distribution in
control samples (Figure 5). A significant increase of the first
quartile (shortest telomeres) representing 50–70% of the cases in
the BRCA1, BRCA2, and BRCAX groups was observed (p=
0.003, p,0.0001, and p,0.0001, respectively). In contrast, the
proportion of cases in the first quartile significantly decreased in
the sporadic breast cancer group compared to the controls (10% of
cases, p=0.0026). These results suggested that familial breast
cancer, BRCA1 and BRCA2, but also a subgroup of BRCAX, was
characterized by short telomeres in peripheral blood cells. We
further stratified BRCAX families based on the number of gene-
rations in which individuals with breast cancer appeared (Table 2).
Thus, there were families in which the proband’s generation was
the first one with affected individuals, and families in which, in
addition to the proband’s generation, there were one or two
additional generations with cancer. Interestingly, those BRCAX
families with only one generation affected corresponded almost
completely to the fourth quartile characterized by the longest
telomeres (Table 2), suggesting that shortening of telomere length
might be occurring in successive generations.
Changes in telomere length in mother-daughter pairs
from breast cancer families
We next investigated the relation between telomere length and
genetic anticipation in breast cancer. We measured changes in
telomere length in 19 mother-daughter pairs from FBOC families
(3 BRCA1, 1 BRCA2, and 15 BRCAX) who developed breast
cancer (Figure 6) (Table 3) and compared them to 16 normal
mother-daughter pairs. We additionally analyzed telomeres in 12
pairs of affected mothers from BRCA1/2 families and their
respective daughters who were mutation carriers but did not
develop cancer to date (Table 4). Telomere length was adjusted for
age and we evaluated telomere differences between mothers and
daughters in the three groups: both mothers and daughters af-
fected, affected mothers and unaffected mutation-carrying daugh-
ters, and mother and daughter controls (Figure 7A). Interestingly,
telomere length significantly decreased not only in affected
daughters (p=0.00018) but also in unaffected daughters who
were carriers of BRCA1/2 mutations (p=0.003), while the change
Figure 3. Comparison of telomere length, adjusted for age, in control women and hereditary and sporadic breast cancer. Age-
adjusted telomere length (calculated as the difference between the observed and the predicted values; see Materials and Methods section)
distribution in peripheral blood leukocytes of control women (n=267); familial breast cancer groups BRCA1 (n=48), BRCA2 (n=45), and BRCAX
(n=105); and sporadic breast cancer (n=71). Bilateral t-tests were performed to compare telomeres of breast cancer groups with the controls and
the respective p-values are represented. Significantly shorter telomeres were found in all hereditary breast cancer groups whereas no significant
differences appeared between controls and sporadic breast cancer cases.
doi:10.1371/journal.pgen.1002182.g003
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significant (p=0.341). This indicates that telomere shortening was
associated in these mother-daughter transmissions to the inheri-
tance of a genetic mutation rather than with the disease. Looking
at the difference in telomere length of mother-daughter pairs
(Figure 7B), significantly larger differences in pairs from affected
families were found compared to controls (p=0.003), with telo-
meres being shorter in daughters of breast cancer families
compared with normal mother-daughter pairs. This decrease in
telomere length in successive generations suggests that telomere
length could explain age anticipation in familial breast cancer.
Discussion
Telomere dysfunction seems to underlie the development of a
range of human genetic, degenerative, aging diseases and cancer
[26]. Our results demonstrated that short telomeres in peripheral
blood cells were a feature of hereditary breast cancer patients and
that telomere shortening frequently occurred with successive
generations in these families, suggesting that telomere shortening
could be the mechanism to explain the phenomenon of age
anticipation in this disease.
Decreasing age of onset in families with hereditary breast cancer
has been observed before [9–11]. Similar to what we have found,
Paterson et al. [10] reported earlier age of diagnosis, of between 6
and 9 years, in successive generations of breast cancer families.
Another study performed in a smaller number of BRCA1, BRCA2
and BRCAX families demonstrated that the mean maternal age at
diagnosis in the BRCA1 group was significantly lower comparing
to the BRCA2 or BRCAX groups, and no significant difference
was found in the mean age at diagnosis between mothers and
daughters in BRCA1 families [9]. In our study we detected lower
anticipation effect in BRCA1 families comparing to BRCA2 or
BRCAX. Since BRCA1 mutations predispose to breast cancer at
an earlier age, it would be more difficult to have large differences
between generations in BRCA1 families. However, there are not
definitive conclusions about whether there exists a real anticipa-
tion phenomenon. We cannot exclude that there would be
alternate explanations for the earlier age of diagnosis in daughters.
This observation could be due to ascertainment bias of subjects
and lead-time bias, as a result of early detection of cancers by
extensive screening or surveillance programs in high risk families
[27,28]. More sophisticated statistical approaches and mechanistic
studies are warranted to answer this complicated problem. To date
there are studies for [10,29,30] and against [28] a real phe-
nomenon of anticipation in breast cancer, but a final conclusion
regarding anticipation is still an open matter that is complicated by
the fact that there is no molecular mechanism to explain it.
Importantly we provide data indicating that telomere shortening is
a possible biological explanation for the complex phenomenon of
anticipation in breast cancer.
There are several studies trying to find association between
short telomeres and risk of breast cancer that have reported
contradictory results [16–19,31,32]. The fact that sporadic breast
cancer showed normal telomere length distribution in our study
agrees with previous results from case-control studies, focused on
sporadic cases, indicating lack of association between telomere
lengths in blood leukocytes with risk of breast cancer [31,32].
Interestingly, one association study reported significant association
with breast cancer risk in women under 50 years of age, but no
association between telomere length and breast cancer in women
50 years of age or older [17]. Hereditary breast cancer, which we
found characterized by short telomeres, typically occurs in women
under 50 years. Then, it seems that hereditary breast cancer is
associated with short telomeres, especially in BRCA1 and BRCA2
mutation carriers, as well as in a subgroup of BRCAX.
It has been reported that telomere attrition may be affected
by factors such as smoking, oxidative stress or obesity [33–35].
Recently a prospective case-control study in breast cancer
suggested that telomere shortening mainly occurs after diagnosis,
as an effect of chemotherapy or other aspects of disease
progression [16]. However, the observed telomere shortening in
unaffected BRCA mutation carrier daughters, as well as shorter
telomere length in hereditary versus sporadic cases, although they
followed similar therapeutic strategies, indicate that telomere
shortening is largely influenced by genetic events. Nevertheless, the
results are limited by the absence of data regarding timing of the
sample draw, and the application of any chemotherapy. Our
results showing that telomeres of affected women from BRCA1 and
BRCA2 families were significantly shorter than normal controls
suggest that these genes might be involved in telomere regulation.
Similarly, we can speculate that other genes involved in telomere
maintenance could also be susceptibility genes that explain at least
part of the BRCAX families with short telomeres.
Telomeres were shorter in affected mutation carriers versus non
carriers and, moreover, we found that telomeres shortened in
successive generations in affected families comparing with con-
trols, suggesting that this is a plausible mechanism explaining the
observed anticipation effect in familial breast cancer. We can
speculate that mutations in BRCA1/2 or other genes induce faster
telomere attrition during life time increasing the probability of
genomic instability and the risk of developing breast cancer. Breast
Figure 4. Telomere length in affected BRCA1/2 mutation
carriers and corresponding non-carrier sisters. Comparison of
age-adjusted telomere length between BRCA1/2 mutation carriers
(n=19) and healthy non-carrier sisters (n=22) from 19 different families
(8 BRCA1, 11 BRCA2) is represented through box-plots showing the
median and interquartile distance for each group. Age-adjusted
telomere length was calculated for each sample as the difference
between the actual and the predicted value using the line of best fit
from controls (see Materials and Methods). Atypical (circles) and
extreme (asterisks) values are also shown. Mann-Whitney U tests
between the groups were performed, and significantly shorter
telomeres were found in mutation carriers versus non-carriers. The
non-carrier sisters from affected families do not show differences in
telomere length with the control women.
doi:10.1371/journal.pgen.1002182.g004
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mutation, as this is the critical risk factor, and then the telomere
length could modify the age at which the cancer would appear, as
shorter telomeres at birth would reach dramatic genetic instability
earlier that longer ones. On the other hand, telomere shortening
could be a process mainly associated with the presence of
mutations in BRCA1/2, or some other genes, regardless of the
disease pathophysiology or age of presentation. Interestingly, we
found four families in which daughters showed shorter telomeres
than their mothers although the age of breast cancer was not
anticipated with respect their mothers (Table 4), indicating that
other genetic modifiers or environmental factors would be also
determining the age of onset of breast cancer.
Telomere length variations as well as different telomere erosion
rates were observed within the different lymphocyte subsets
[36,37]. In our study we used unselected peripheral blood leu-
kocytes to estimate telomere lengths and then it could be affected
by cell-to-cell variations. Selection of specific lymphocyte subpop-
ulation would provide a more refined knowledge of the role that
telomere length could have in cancer risk assessment.
The fact that telomere shortening has been associated with
anticipation in other diseases, such as dyskeratosis congenita [13],
as well as Li-Fraumeni Syndrome [7], suggest that telomere
shortening may be responsible for genetic anticipation in a wide
spectrum of genetic diseases.
Our findings indicate that the study of telomere length would be
of relevance in the clinical surveillance and design of appropriate
screening tests for patients with familial breast cancer.
Materials and Methods
Samples
Informed consent was obtained for all patients involved in this
study and the research project has the approval of the ethics
Figure 5. Distribution of hereditary and sporadic breast cancer cases by quartiles of telomere length. First quartile (Q1), characterized
by the shortest telomeres, was significantly increased in the three hereditary groups, but decrease in the sporadic breast cancer. For analysis of
differences in the proportion of cases in Q1 in breast cancer groups and controls, Chi-square test two-sided was performed.
doi:10.1371/journal.pgen.1002182.g005
Table 2. Distribution of BRCAX families in the quartiles of telomere length.
1 Generation affected 2 Generations affected 3 Generations affected
Quartiles n ( % )n( % ) n( % )
Q1 0 (0) 26 (50) 23 (53)
Q2 0 (0) 12 (23) 10 (23)
Q3 1 (11.1) 5 (10) 3 (7)
Q4 8 (88.9) 9 (17) 7 (16)
Total 95 2 4 3
BRCAX families were stratified according to the number of generations with affected breast cancer cases and distributed into the quartiles of telomere length.
doi:10.1371/journal.pgen.1002182.t002
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selected from the register of the Familial Cancer Consultation of
the CNIO Human Genetics Group. All of them fulfilled the high
risk criteria for genetic testing [38]. Index cases had been screened
for mutations in BRCA1 and BRCA2 by a combination of DHPLC
and direct sequencing as previously reported [39]. A total of 623
breast cancer high-risk families (40 BRCA1,6 6BRCA2, and 531
families without mutations in BRCA1/2) which included 758
mother-daughter pairs affected with breast cancer were selected
to analyze the anticipation effect in the age of onset. To avoid
differences in the age of onset of different types of tumors oc-
curring in these families, i.e. breast, ovary, and other tumors, only
mother-daughter pairs who developed breast tumors were used to
estimate the anticipation effect.
Telomere length in familial breast cancer cases was analyzed
using DNA extracted from peripheral blood leukocytes in index
cases from a set of 198 Spanish breast cancer families cor-
responding to 48 BRCA1, 45 BRCA2, and 105 BRCAX families.
In these three groups the distribution of ages at which the telomere
were analyzed was for BRCA1 a mean of 43 years (range, 18–61),
mean 48 years (range, 21–71) for BRCA2 cases and for BRCAX
cases a mean of 48 years (range, 25–70). These samples
corresponded to women with familial breast cancer who met the
high risk criteria and attended the Spanish National Cancer
Centre family cancer clinics between 2002 and 2009. In addition,
samples from 8 affected BRCA1 mutations carriers and sisters not
carrying the mutation, and 11 samples from affected BRCA2
mutations carriers and 14 healthy sisters without mutation from
these families were included to study the relation between telomere
length and the presence of an inherited mutation under the same
genetic background.
DNA samples from 267 control women with a mean age of 46
years (range, 23 to 70 years) were also analyzed to compare
normal telomere length distribution with that in breast cancer
patients. Controls corresponded to Spanish healthy women
without personal or familial antecedents of cancer, recruited at
different Hospitals in Spain for different epidemiologic studies
[40]. Age distribution of controls was homogeneous enough to
demonstrate the expected decline of telomere length with age.
Seventy-one peripheral blood samples from a group of women
with sporadic breast cancer at ages ranging from 31 to 61, mean
53 years, were also analyzed. These sporadic cases were con-
secutive newly diagnosed breast cancer patients, without familial
antecedents of breast cancer, recruited between 2006 and 2007 in
the different Hospitals in Madrid. These cases were included in
previous studies from our group [40,41].
Telomere-length quantification
Genomic DNA was automatically extracted from peripheral
blood mononuclear cells using the MagNA Pure LC 2.0 System
(Roche). Telomere length was measured using a quantitative
PCR-based technique previously described [42,43]. By this
Figure 6. Familial breast cancer pedigrees showing anticipation in the age of onset of breast cancer. Open circles (females) and squares
(males) represent normal individuals and black circles represent affected females. Age of breast cancer diagnosis is shown for affected women.
Mother-daughter pairs where the telomere length was studied are highlighted and age-adjusted telomere length for each pair is represented in the
graphic below the pedigrees.
doi:10.1371/journal.pgen.1002182.g006
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Mother Daughter
Fam Type Tumor
Age at diagnosis
(years)
Telomere (age-
adjusted) Tumor
Age at diagnosis
(years)
Telomere (age-
adjusted)
1 1190-M
a BRCA1 BR+OV 44 20.18229 BR Bi 45 20.49235
2 1190-M BRCA1 BR+OV 44 20.18229 BR Bi 31 20.52641
3 1195-M BRCA1 BR Bi 54 0.51041 BR 28 20.1384
4 0921-M BRCA2 BR Bi 46 0.02561 BR 36 20.45342
5 192-M
a BRCAX BR 42 0.72125 BR 42 20.8601
6 330-M BRCAX BR 55 20.05267 BR 42 20.56179
7 401-M BRCAX BR Bi 55 20.18586 BR 28 20.79633
8 1109-M BRCAX BR 70 20.30786 BR 40 20.37053
9 21-M BRCAX BR 45 0.48848 BR 31 20.11345
10 1528-03-M BRCAX BR 52 0.36643 BR 45 20.14667
11 1885-04-M
a BRCAX BR 50 0.59976 BR 60 0.19095
12 199-M BRCAX BR 59 20.5391 BR+Leu 24 20.1421
13 599-M BRCAX BR 55 0.42882 BR 39 20.40432
14 621-M BRCAX BR 59 0.43238 BR 25 0.0499
15 902-M BRCAX BR 51 0.18553 BR+Mel 40 20.32889
16 934-M BRCAX BR 70 0.59847 BR 43 0.07029
17 988-M
a BRCAX BR 35 20.04272 BR 37 20.55533
18 1288-M BRCAX BR Bi 51 0.28299 BR 33 20.10973
19 1227-M BRCAX BR 74 0.0569 BR 43 20.28305
Data from the mother-daughter pairs with familial breast cancer showing the age of breast cancer diagnosis and the age-adjusted telomere length.
BR: Breast cancer, BR Bi: Bilateral Breast cancer, OV: Ovarian cancer, Leu: Leukemia, Mel: Melanoma
aFamilies not showing anticipation in the age of onset.
doi:10.1371/journal.pgen.1002182.t003
Table 4. Age-adjusted telomere length in mother-daughter pairs with unaffected BRCA1/2 carrier daughters.
Mother Daughter
Fam Type Tumor
Age at diagnosis
(years)
Telomere
(age-adjusted) Tumor
Age at interview
(years)
Telomere
(age-adjusted)
1 0901-M BRCA1 BR 52 0.15442 2 25 20.71764
2 2 28 0.40677
3 1190-M BRCA1 BR+OV 44 20.18229 2 42 20.36214
4 0951-M BRCA1 BR+OV 41 20.33339 2 21 20.72402
5 1521-M BRCA1 BR 39 20.2273 2 27 20.70288
6 0836-M BRCA2 BR 41 20.56158 2 24 20.34418
7 1145-M BRCA2 BR 57 20.11092 2 41 20.34752
8 2 37 20.48726
9 0921-M BRCA2 BR Bi 46 0.02561 2 31 20.58487
10 1456-M BRCA2 BR Bi 48 20.11339 2 26 20.61877
11 1005-M BRCA2 BR 69 20.07681 2 35 20.56699
12 2 32 20.40273
Data from the mother-daughter pairs from familial breast cancer families showing the age of breast cancer diagnosis, or age at interview of unaffected daughters, and
the age-adjusted telomere length.
BR: Breast cancer, BR Bi: Bilateral Breast cancer, OV: Ovarian cancer.
doi:10.1371/journal.pgen.1002182.t004
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repeat copy number (T) and a single-copy gene, 36B4, copy
number (S). Primers used to amplify telomere repeats and the
36B4 gene were described before [43]. DNA samples were
amplified in a total reaction volume of 10 ml containing 1x Power
SYBR Green PCR Master Mix (Applied Biosystems), 300 nM of
primer Tel1, 900 nM of primer Tel2, and 30 ng of DNA. For
36B4 reactions the concentrations of primers were 300 nM of
36B4u and 500 nM of 36B4d. All samples, for both telomere and
36B4 amplifications, were analyzed in triplicate using an ABI
7900HT thermal cycler, in 384-well format. A robot Biomek NXp
(Beckman Coulter) was used to load DNA and PCR mixes into the
384 PCR plates. The thermal cycling profile was the same for both
assays: 95uC incubation for 10 minutes followed by 35 cycles of
95uC for 15 seconds, 54uC for 2 minutes, and 72uC for 15 seconds.
Each PCR reaction plate included two samples (DNA from the
MBA-MD-436 cell line) to be used for inter-run calibration. DNA
from the cell line MBA-MD-436 was used to construct a standard
serial dilution series (1/4 dilutions starting from 50 ng) for PCR
efficiency calculation. We observed that over 100 ng linearity is
lost, and therefore samples were diluted to 10 to 30 ng for proper
measurements. The amplification efficiencies (E) of each PCR
were calculated from the slopes of the standard curves according
to Eff=10
(21/slope). The efficiency was calculated for each plate,
both for the telomere and for the 36B4 signal. PCR data was
analyzed using the SDS 2.2.2 program. The threshold value was
established in the initial part of the exponential phase of the
amplification curves and the crossing of this line with the curve
defines the threshold cycle value (Ct) for all samples. For each
sample the relative concentration of both Telomere (T) and 36B4
(S) was calculated relative to the calibration sample and PCR
efficiency to obtain the T/S ratio, as previously described [14],
applying the following formula:
T=S~
Efftel,sample
   {ct tel,sample ðÞ
Eff36B4,sample
   {ct 36B4,sample ðÞ
,
Efftel,calibrator ðÞ
{ct tel,calibrator ðÞ
Eff36B4,calibrator ðÞ
{ct 36B4,calibrator ðÞ
Concordance among triplicates was checked, and the coefficient
of variation was obtained for Telomere (average 0.85%, range
0.2–2.8%) and 36B4 (average 0.54%, range 0.12–1.5%). Repro-
ducibility was tested by repeating two samples in all experiments.
Good agreement between measurements were found throughout
the experiments (r=0.86).
Statistical analysis
To asses telomere length differences between control samples
and hereditary and sporadic breast cancer cases, telomere length
measurements were adjusted for age using the line of best fit for
controls. Thus, the difference between the actual and the predicted
value was calculated for each sample. Differences in age-adjusted
telomere lengths were analyzed by bilateral t-tests.
The Kolmogorov-Smirnov test was used to evaluate normality
in telomere length of BRCA1/2 mutation carriers and their
Figure 7. Changes in telomere length between mother-daughter pairs. (A) Box-plots representing telomere length distribution in mothers
and daughters affected with breast cancer, affected mothers and daughters unaffected but carrying BRCA1/2 mutations, and control mothers and
daughters. Significant differences were found in mother-daughter pairs from familial breast cancer families with a decrease in the telomere length in
both affected and unaffected, mutation-carrying daughters, but not in controls. (B) Generational changes in telomere length in mother-daughter
pairs with familial breast cancer (n=19) compared to control mother-daughter pairs (n=16). Differences between age-adjusted telomere length in
daughters and age-adjusted telomere length of the corresponding mother were obtained for affected and control groups. Median value is drawn as a
horizontal line for each group. Telomeres of affected daughters were significantly shorter than those of their mothers, compared to the changes
observed in control mother-daughter pairs (Mann-Whitney U, p-value=0.003).
doi:10.1371/journal.pgen.1002182.g007
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not be assumed, a Mann-Whitney U test was applied to evaluate
distribution differences. A similar analysis was done in order to
assess generational differences in telomere length between control
mother-daughter pairs and mother-daughter pairs from FBOC
families. Statistical calculations were performed using SPSS
version 17 (SPSS Inc, Chicago, Illinois). Nominal two-sided P-
values less than 0.05 were considered statistically significant.
Due to limitations of previous information regarding telomere
length in the population studied, a post hoc power analysis for
comparisons of telomere length among the different groups was
made. Power analysis for the test between controls and sporadic
cases, which showed no significant differences in telomere length,
was 63%.
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